BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:tanruprubart readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of tanruprubart\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07020819-10858@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:tanruprubart: Phase 3 readout est. (NCT07020819)
DESCRIPTION:tanruprubart\, phase 3\, Guillain-Barré Syndrome.\nStudy: An O
 pen Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as 
 ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)\nEst
 imated primary completion: 31 May 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tanruprubart#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07020819
URL:https://assetmemo.bio/drug/tanruprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
